000281916 001__ 281916
000281916 005__ 20251112112018.0
000281916 0247_ $$2doi$$a10.1136/bmjopen-2025-103998
000281916 0247_ $$2pmid$$apmid:41213698
000281916 0247_ $$2pmc$$apmc:PMC12598993
000281916 037__ $$aDZNE-2025-01258
000281916 041__ $$aEnglish
000281916 082__ $$a610
000281916 1001_ $$00009-0008-6844-1968$$aHerr, Thorsten$$b0
000281916 245__ $$aEffect of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) on non-motor symptoms in multiple sclerosis: study protocol for a randomised, controlled trial.
000281916 260__ $$aLondon$$bBMJ Publishing Group$$c2025
000281916 3367_ $$2DRIVER$$aarticle
000281916 3367_ $$2DataCite$$aOutput Types/Journal article
000281916 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762942687_29014
000281916 3367_ $$2BibTeX$$aARTICLE
000281916 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281916 3367_ $$00$$2EndNote$$aJournal Article
000281916 520__ $$aResearch in people with relapsing remitting multiple sclerosis (PwRRMS) is increasingly focusing on non-motor symptoms like cognitive impairment, fatigue and depression. Due to the high negative impact on quality of life and high socioeconomic costs based on these symptoms, more specific research to improve non-motor symptoms is needed. Transcutaneous auricular vagus nerve stimulation (taVNS) has been found to be a cognitive enhancer in preclinical research and was successfully used for the treatment of psychiatric and neurological disorders to combat dysfunctional cognitive and affective processes. However, the capacity of taVNS to improve cognitive and other non-motor symptoms in PwRRMS has not been tested yet. The aim of this study is to evaluate the therapeutic potential of taVNS on cognitive processing speed. Based on ample evidence demonstrating that taVNS promotes adaptive cognitive and affective processes, we hypothesised that taVNS would alleviate cognitive processing speed in PwRRMS.This study protocol describes the prospective, single-centre, SHAM-controlled, single-blinded trial with a planned sample size of 60 participants (30 PwRRMS, with a diagnosis of multiple sclerosis according to McDonald criteria and 30 healthy controls; age: 18-50 years). The Symbol Digit Modalities Test (SDMT) will be used to determine cognitive processing speed, Beck Depression Inventory-II to determine depression and Fatigue Scale for Motor and Cognitive Functions to determine fatigue. The severity of multiple sclerosis will be assessed using the Expanded Disability Status Scale. After baseline assessment, a taVNS protocol (duration: 30 min, tolerance threshold, pulse width: 250 μs, stimulation frequency: 25 Hz, 30 s on/30 s off) will be applied, followed by post-intervention assessment.The study was reviewed and approved by the local ethics committee of the University Medical Centre Greifswald (study reference number: BB137/24).www.drks.de, number: DRKS00034912. Study results will be disseminated through academic conferences as well as peer-reviewed publications.DRKS00034912.
000281916 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281916 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281916 650_7 $$2Other$$aMultiple sclerosis
000281916 650_7 $$2Other$$aNEUROPHYSIOLOGY
000281916 650_7 $$2Other$$aNeurophysiology
000281916 7001_ $$aGamain, Julie$$b1
000281916 7001_ $$aStrauss, S.$$b2
000281916 7001_ $$aSzeska, C.$$b3
000281916 7001_ $$0P:(DE-2719)2812683$$aFlöel, Agnes$$b4
000281916 7001_ $$aPenner, Iris-Katharina$$b5
000281916 7001_ $$00000-0002-3968-9656$$aWeymar, Mathias$$b6
000281916 7001_ $$aGrothe, M.$$b7
000281916 773__ $$0PERI:(DE-600)2599832-8$$a10.1136/bmjopen-2025-103998$$gVol. 15, no. 11, p. e103998 -$$n11$$pe103998$$tBMJ open$$v15$$x2044-6055$$y2025
000281916 8564_ $$uhttps://pub.dzne.de/record/281916/files/DZNE-2025-01258.pdf$$yRestricted
000281916 8564_ $$uhttps://pub.dzne.de/record/281916/files/DZNE-2025-01258.pdf?subformat=pdfa$$xpdfa$$yRestricted
000281916 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812683$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000281916 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281916 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMJ OPEN : 2022$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-24T13:10:16Z
000281916 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-24T13:10:16Z
000281916 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-01-24T13:10:16Z
000281916 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-19
000281916 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-19
000281916 9201_ $$0I:(DE-2719)5000081$$kAG Flöel$$lDementia Prevention – Mechanisms and Clinical Implementation$$x0
000281916 980__ $$ajournal
000281916 980__ $$aEDITORS
000281916 980__ $$aVDBINPRINT
000281916 980__ $$aI:(DE-2719)5000081
000281916 980__ $$aUNRESTRICTED